| A practical concept for preoperative management of patients with impaired primary hemostasis. | |
| | |
MedLine Citation:
|
PMID: 15094936 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
In a prospective study, 254 of 5649 unselected patients scheduled for surgery at our hospital were identified preoperatively as having either acquired (n=182) or inherited (n=72) impaired primary hemostasis (platelet dysfunction including von Willebrand disease). All patients were initially pretreated with desmopressin (DDAVP). Response to DDAVP or subsequent treatment(s) was defined as correction of any one of the abnormal PFA-100 platelet function tests. The non-responders were additionally treated with tranexamic acid or aprotinin; those with von Willebrand disease (vWD) received factor VIII concentrates with von Willebrand factor (vWF). Those still unresponsive to therapy received conjugated estrogens and, as a last attempt, a platelet transfusion. The administration of DDAVP led to a correction of platelet dysfunction in 229 of the 254 patients treated (90.2%). Tranexamic acid was effective in 12 of 16, aprotinin in 3 of 5, and factor VIII concentrates with vWF in all 4 patients with unresponsive to DDAVP. The remaining 6 patients were pretreated with conjugated estrogens, and 2 of these patients were additionally treated with platelet transfusion. The frequency of blood transfusion was lower, but not statistically significant (9.4% vs. 12.2%: p = 0.202) in preoperatively treated patients with impaired hemostasis than in patients without impaired hemostasis. In a retrospective group, the frequency of blood transfusion was statistically significant higher (89.3% vs. 11.3%: p < 0.001) in patients without preoperative correction of impaired hemostasis than in patients without impaired hemostasis. Preoperative correction of impaired primary hemostasis is possible in nearly all patients affected, and results in a reduction of homologous blood transfusions. |
| | |
Authors:
|
Juergen Koscielny; Georg-Friedrich von Tempelhoff; Sabine Ziemer; Hartmut Radtke; Michael Schmutzler; Pranav Sinha; Abdulgabar Salama; Holger Kiesewetter; Reinhard Latza |
Related Documents
:
|
10758466 - A retrospective survey of fibrinolysis as an indicator of poor outcome after cardiopulm... 14076376 - Some aspects of haemostasis after open-heart surgery. 8167556 - Monocyte tissue factor in treated hodgkin's disease. 22349136 - Serum il-33 but not st2 level is elevated in intermittent allergic rhinitis and is a ma... 20236196 - Paederus dermatitis in egypt: a clinicopathological and ultrastructural study. 3517236 - Cerebrospinal fluid lysozyme and beta 2-microglobulin in neurosarcoidosis. |
Publication Detail:
|
Type: Clinical Trial; Journal Article |
Journal Detail:
|
Title: Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis Volume: 10 ISSN: 1076-0296 ISO Abbreviation: Clin. Appl. Thromb. Hemost. Publication Date: 2004 Apr |
Date Detail:
|
Created Date: 2004-04-19 Completed Date: 2004-11-16 Revised Date: 2009-11-19 |
Medline Journal Info:
|
Nlm Unique ID: 9508125 Medline TA: Clin Appl Thromb Hemost Country: United States |
Other Details:
|
Languages: eng Pagination: 155-66 Citation Subset: IM |
Affiliation:
|
Institute for Transfusion Medicine, Charité Humboldt-University, Schumannstr. 20/21, 10117 Berlin, Germany. juergen.koscielny@charite.de |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adolescent Adult Aged Aged, 80 and over Bleeding Time Blood Platelet Disorders / drug therapy, physiopathology, surgery, therapy* Blood Platelets / drug effects, metabolism Blood Transfusion Deamino Arginine Vasopressin / pharmacology Female Hemostasis* Humans Male Middle Aged Preoperative Care* von Willebrand Diseases / drug therapy, physiopathology, surgery |
| Chemical | |
Reg. No./Substance:
|
16679-58-6/Deamino Arginine Vasopressin |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: CYP2C9 genetic polymorphisms and warfarin.
Next Document: Effect of ticlopidine on monocyte-derived microparticles and activated platelet markers in diabetes ...